{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:05:31Z","timestamp":1790867131376,"version":"4.1.0"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      The lepromatous leprosy (LL) disease is caused by\n                      <jats:italic toggle=\"yes\">Mycobacterium leprae<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">Mycobacterium lepromatosis<\/jats:italic>\n                      which is characterized by inadequate response to treatment, a propensity to drug resistance, and patient disability. We aimed to evaluate current immunomodulatory medicines and their target proteins collectively as a drug repurposing strategy to decipher novel uses for LL.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A dataset of human genes associated with LL-immune response was retrieved from public health genomic databases including the Human Genome Epidemiology Navigator and DisGeNET. Retrieved genes were filtered and enriched to set a robust network (\u226510, up to 21 edges) and analyzed in the Cytoscape program (v3.9). Drug associations were obtained in the NDEx Integrated Query (v1.3.1) coupled with drug databases such as ChEMBL, BioGRID, and DrugBank. These networks were analyzed in Cytoscape with the CyNDEx-2 plugin and STRING protein network database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Pathways analyses resulted in 100 candidate drugs organized into pharmacological groups with similar targets and filtered on 54 different drugs. Gene-target network analysis showed that the main druggable targets associated with LL were tumoral necrosis factor-alpha, interleukin-1B, and interferon-gamma. Consistently, glucosamine, binimetinib, talmapimod, dilmapimod, andrographolide, and VX-702 might have a possible beneficial effect coupled with LL treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Based on our drug repurposing analysis, immunomodulatory drugs might have a promising potential to be explored further as therapeutic options or to alleviate symptoms in LL patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijmy.ijmy_105_23","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T16:34:01Z","timestamp":1725294841000},"page":"388-393","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Bioinformatic Approach for Repurposing Immunomodulatory Drugs for Lepromatous Leprosy"],"prefix":"10.4103","volume":"12","author":[{"given":"Gary J.","family":"Espitia","sequence":"first","affiliation":[{"name":"Group Basic Sciences in Health, Faculty of Medicine, Fundaci\u00f3n Universitaria de Ciencias de la Salud-FUCS, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson Enrique","family":"Arenas","sequence":"additional","affiliation":[{"name":"Group of Tropical Dermatology, Hospital Universitario Centro Dermatol\u00f3gico Federico Lleras Acosta, Colombia"},{"name":"Department of Biology, Faculty of Sciences, Universidad Antonio Nari\u00f1o, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6155-3771","authenticated-orcid":false,"given":"Luz Dary","family":"Guti\u00e9rrez-Casta\u00f1eda","sequence":"additional","affiliation":[{"name":"Group Basic Sciences in Health, Faculty of Medicine, Fundaci\u00f3n Universitaria de Ciencias de la Salud-FUCS, Colombia"},{"name":"Group of General Dermatology, Centro Dermatol\u00f3gico Federico Lleras Acosta, Colombia"},{"name":"Department of Basic Sciences, Group Basic Sciences in Health, University Children Hospital of San Jos\u00e9, Bogota, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha In\u00edrida","family":"Guerrero","sequence":"additional","affiliation":[{"name":"Group of Tropical Dermatology, Hospital Universitario Centro Dermatol\u00f3gico Federico Lleras Acosta, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,12,15]]},"reference":[{"key":"R2-20240902","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/j.1365-4632.2011.05414.x","article-title":"The leprosy agents Mycobacterium lepromatosis and Mycobacterium leprae in Mexico","volume":"51","author":"Han","year":"2012","journal-title":"Int J Dermatol"},{"key":"R3-20240902","doi-asserted-by":"crossref","first-page":"698588","DOI":"10.3389\/fmicb.2021.698588","article-title":"Mycobacterium lepromatosis as a second agent of Hansen's disease","volume":"12","author":"Deps","year":"2021","journal-title":"Front Microbiol"},{"key":"R4-20240902","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1309\/AJCPP72FJZZRRVMM","article-title":"Anew Mycobacterium species causing diffuse lepromatous leprosy","volume":"130","author":"Han","year":"2008","journal-title":"Am J Clin Pathol"},{"key":"R5-20240902","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1073\/pnas.1421504112","article-title":"Insight into the evolution and origin of leprosy bacilli from the genome sequence of Mycobacterium lepromatosis","volume":"112","author":"Singh","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R6-20240902","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.clindermatol.2019.01.002","article-title":"Leprosy: A great imitator","volume":"37","author":"Kundakci","year":"2019","journal-title":"Clin Dermatol"},{"key":"R7-20240902","first-page":"87","article-title":"Gerhard Henrik Armauer Hansen \u2013 A legend","volume":"1","author":"Kannan","year":"2019","journal-title":"J Skin Sex Transm Dis"},{"key":"R8-20240902","first-page":"658","article-title":"Gene association with leprosy: A review of published data","volume":"6","author":"Mazini","year":"2015","journal-title":"Front Immunol"},{"key":"R9-20240902","doi-asserted-by":"crossref","first-page":"104581","DOI":"10.1016\/j.meegid.2020.104581","article-title":"Molecular epidemiology of leprosy: An update","volume":"86","author":"Avanzi","year":"2020","journal-title":"Infect Genet Evol"},{"key":"R10-20240902","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40475-018-0145-7","article-title":"Leprosy in Colombia","volume":"5","author":"Cardona-Castro","year":"2018","journal-title":"Curr Trop Med Rep"},{"key":"R11-20240902","doi-asserted-by":"crossref","first-page":"e0005598","DOI":"10.1371\/journal.pntd.0005598","article-title":"Whole genome sequencing distinguishes between relapse and reinfection in recurrent leprosy cases","volume":"11","author":"Stefani","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"R12-20240902","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1007\/s13311-021-01153-z","article-title":"Treatment and evaluation advances in leprosy neuropathy","volume":"18","author":"Ebenezer","year":"2021","journal-title":"Neurotherapeutics"},{"key":"R13-20240902","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000517993","article-title":"Cyclosporin A as an alternative neuroimmune strategy to control neurites and recover neuronal tissues in leprosy","volume":"29","author":"Jesus","year":"2022","journal-title":"Neuroimmunomodulation"},{"key":"R14-20240902","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/ijd.12793","article-title":"Effectiveness and safety of clofazimine and pentoxifylline in type 2 lepra reaction: A double-blind, randomized, controlled study","volume":"54","author":"Roy","year":"2015","journal-title":"Int J Dermatol"},{"key":"R15-20240902","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1080\/14740338.2021.1991307","article-title":"Thalidomide: History, withdrawal, renaissance, and safety concerns","volume":"20","author":"Vargesson","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"R16-20240902","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/14740338.2021.1953467","article-title":"Comparative analysis of the use and control of thalidomide in Brazil and different countries: Is it possible to say there is safety?","volume":"21","author":"de Jesus","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"R17-20240902","doi-asserted-by":"crossref","first-page":"i68","DOI":"10.1093\/bioinformatics\/btac240","article-title":"From drug repositioning to target repositioning: Prediction of therapeutic targets using genetically perturbed transcriptomic signatures","volume":"38","author":"Namba","year":"2022","journal-title":"Bioinformatics"},{"key":"R18-20240902","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"R19-20240902","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.7150\/ijbs.24612","article-title":"Review of drug repositioning approaches and resources","volume":"14","author":"Xue","year":"2018","journal-title":"Int J Biol Sci"},{"key":"R20-20240902","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/omi.2022.0068","article-title":"Multi-omics and artificial intelligence-guided drug repositioning: Prospects, challenges, and lessons learned from COVID-19","volume":"26","author":"Cong","year":"2022","journal-title":"OMICS"},{"key":"R21-20240902","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/ng0208-124","article-title":"A navigator for human genome epidemiology","volume":"40","author":"Yu","year":"2008","journal-title":"Nat Genet"},{"key":"R22-20240902","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1016\/j.csbj.2021.05.015","article-title":"The DisGeNET cytoscape app: Exploring and visualizing disease genomics data","volume":"19","author":"Pi\u00f1ero","year":"2021","journal-title":"Comput Struct Biotechnol J"},{"key":"R23-20240902","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources","volume":"4","author":"Huang da","year":"2009","journal-title":"Nat Protoc"},{"key":"R24-20240902","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: A software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res"},{"key":"R25-20240902","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.12688\/f1000research.9090.1","article-title":"AutoAnnotate: A Cytoscape app for summarizing networks with semantic annotations","volume":"5","author":"Kucera","year":"2016","journal-title":"F1000Res"},{"key":"R26-20240902","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41596-018-0103-9","article-title":"Pathway enrichment analysis and visualization of omics data using g: Profiler, GSEA, Cytoscape and EnrichmentMap","volume":"14","author":"Reimand","year":"2019","journal-title":"Nat Protoc"},{"key":"R28-20240902","doi-asserted-by":"crossref","first-page":"W357","DOI":"10.1093\/nar\/gkz382","article-title":"SwissTargetPrediction: Updated data and new features for efficient prediction of protein targets of small molecules","volume":"47","author":"Daina","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"R29-20240902","doi-asserted-by":"crossref","first-page":"D605","DOI":"10.1093\/nar\/gkaa1074","article-title":"The STRING database in 2021: Customizable protein-protein networks, and functional characterization of user-uploaded gene\/measurement sets","volume":"49","author":"Szklarczyk","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"R30-20240902","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J Biomed Sci"},{"key":"R31-20240902","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4269\/ajtmh.18-0256","article-title":"Alternate anti-leprosy regimen for multidrug therapy refractory leprosy: A retrospective study from a tertiary care center in North India","volume":"100","author":"Narang","year":"2019","journal-title":"Am J Trop Med Hyg"},{"key":"R32-20240902","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.2174\/1386207325666211007110638","article-title":"Repurposing drugs to combat drug resistance in leprosy: A review of opportunities","volume":"25","author":"Sharma","year":"2022","journal-title":"Comb Chem High Throughput Screen"},{"key":"R33-20240902","doi-asserted-by":"crossref","first-page":"e0008678","DOI":"10.1371\/journal.pntd.0008678","article-title":"Thalidomide in the treatment of erythema nodosum leprosum (ENL) in an outpatient setting: A five-year retrospective analysis from a leprosy referral Centre in India","volume":"14","author":"Upputuri","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"R34-20240902","first-page":"D01","article-title":"Azathioprine in chronic recalcitrant erythema nodosum leprosum: A case report","volume":"11","author":"Jitendra","year":"2017","journal-title":"J Clin Diagn Res"},{"key":"R35-20240902","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/antibiotics10010091","article-title":"The prospect of repurposing immunomodulatory drugs for adjunctive chemotherapy against tuberculosis: A critical review","volume":"10","author":"Lee","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"R36-20240902","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1517\/17460441.2013.826188","article-title":"The eradication of leprosy: Molecular modeling techniques for novel drug discovery","volume":"8","author":"Anusuya","year":"2013","journal-title":"Expert Opin Drug Discov"},{"key":"R37-20240902","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4103\/0019-5154.74528","article-title":"Leprosy therapy, past and present: Can we hope to eliminate it?","volume":"55","author":"Prasad","year":"2010","journal-title":"Indian J Dermatol"},{"key":"R38-20240902","doi-asserted-by":"crossref","first-page":"e0004335","DOI":"10.1371\/journal.pntd.0004335","article-title":"Mycobacterium leprae-infected macrophages preferentially primed regulatory T cell responses and was associated with lepromatous leprosy","volume":"10","author":"Yang","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"R39-20240902","doi-asserted-by":"crossref","first-page":"918009","DOI":"10.3389\/fmicb.2022.918009","article-title":"Modulation of the response to Mycobacterium leprae and pathogenesis of leprosy","volume":"13","author":"Cabral","year":"2022","journal-title":"Front Microbiol"},{"key":"R40-20240902","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00403-013-1411-0","article-title":"Assessment of serum level of interleukin-1b and interleukin-12 in leprosy: Impact of previous Bacillus Calmitte Guerin vaccination","volume":"306","author":"Sallam","year":"2014","journal-title":"Arch Dermatol Res"},{"key":"R41-20240902","doi-asserted-by":"crossref","first-page":"9188","DOI":"10.1073\/pnas.0501196102","article-title":"Insights into regulation of human Schwann cell proliferation by Erk1\/2 via a MEK-independent and p56Lck-dependent pathway from leprosy bacilli","volume":"102","author":"Tapinos","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R42-20240902","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ejphar.2011.08.046","article-title":"Thalidomide modulates Mycobacterium leprae-induced NF-kB pathway and lower cytokine response","volume":"670","author":"Hernandez Mde","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"R43-20240902","doi-asserted-by":"crossref","first-page":"482","DOI":"10.4103\/idoj.IDOJ_561_19","article-title":"What is new in the pathogenesis and management of erythema nodosum leprosum","volume":"11","author":"Bhat","year":"2020","journal-title":"Indian Dermatol Online J"},{"key":"R44-20240902","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4103\/ijd.IJD_684_20","article-title":"A study on the impact of genetic polymorphisms of cytokines TNF\u03b1, IFN\u03b3 and IL10 in South Indian leprosy patients","volume":"66","author":"Kolla","year":"2021","journal-title":"Indian J Dermatol"},{"key":"R45-20240902","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/eji.201948283","article-title":"Improved Mycobacterium tuberculosis clearance after the restoration of IFN-\u03b3(+) TNF-\u03b1(+) CD4(+) T cells: Impact of PD-1 inhibition in active tuberculosis patients","volume":"50","author":"Kamboj","year":"2020","journal-title":"Eur J Immunol"},{"key":"R46-20240902","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4269\/ajtmh.19-0616","article-title":"Biologics in leprosy: A systematic review and case report","volume":"102","author":"Cogen","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"R47-20240902","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1053\/j.seminoncol.2015.09.023","article-title":"MEK1\/2 inhibitors: Molecular activity and resistance mechanisms","volume":"42","author":"Wu","year":"2015","journal-title":"Semin Oncol"},{"key":"R48-20240902","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/17512433.2019.1570847","article-title":"Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations","volume":"12","author":"Trojaniello","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R49-20240902","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/jsfa.4660","article-title":"Effect of a dietary supplement containing glucosamine hydrochloride, chondroitin sulfate and quercetin glycosides on symptomatic knee osteoarthritis: A randomized, double-blind, placebo-controlled study","volume":"92","author":"Kanzaki","year":"2012","journal-title":"J Sci Food Agric"},{"key":"R50-20240902","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.fct.2004.11.006","article-title":"Glucosamine effects in humans: A review of effects on glucose metabolism, side effects, safety considerations and efficacy","volume":"43","author":"Anderson","year":"2005","journal-title":"Food Chem Toxicol"},{"key":"R51-20240902","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1517\/13543780903321490","article-title":"The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer","volume":"18","author":"Yong","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"R52-20240902","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nrg3932","article-title":"Human genotype-phenotype databases: Aims, challenges and opportunities","volume":"16","author":"Brookes","year":"2015","journal-title":"Nat Rev Genet"},{"key":"R53-20240902","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.tips.2019.06.003","article-title":"Insights into computational drug repurposing for neurodegenerative disease","volume":"40","author":"Paranjpe","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"R54-20240902","doi-asserted-by":"crossref","first-page":"724277","DOI":"10.3389\/fimmu.2021.724277","article-title":"Drug repurposing for atopic dermatitis by integration of gene networking and genomic information","volume":"12","author":"Adikusuma","year":"2021","journal-title":"Front Immunol"},{"key":"R55-20240902","doi-asserted-by":"crossref","first-page":"e0267095","DOI":"10.1371\/journal.pone.0267095","article-title":"Discovery of new drug indications for COVID-19: A drug repurposing approach","volume":"17","author":"Kumari","year":"2022","journal-title":"PLoS One"}],"container-title":["The International Journal of Mycobacteriology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_105_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:33:27Z","timestamp":1787772807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_105_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmy.ijmy_105_23","relation":{},"ISSN":["2212-5531","2212-554X"],"issn-type":[{"value":"2212-5531","type":"print"},{"value":"2212-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"2023-05-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}